Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Diagnostic
|Official Title:||Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT|
- Preferred Contrast Agent [ Time Frame: 1 Day ]The primary outcome variable is the taste test when subjects will be asked which preparation they prefer. Possible answers include Onmipaque, Gastroview or neither.
- Bowel Opacification Score [ Time Frame: Collected day of study ]The bowel opacification score was calculated by adding values for stomach, duodenum, jejunum and ileum for each patient. They were averaged across two doctors who read the studies. Scores can range from 0 (no opacification) to 3 (excellent) for each segment and from 0 to 12 for bowel opacification score.
|Study Start Date:||August 2007|
|Study Completion Date:||March 2009|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
Active Comparator: 1
Oral CT contrast
Other Name: diatrizoate meglumine and diatrizoate sodium solution USP
Oral CT contrast
Other Name: Iohexol
Hide Detailed Description
Participants must be scheduled for a CT scan prior to enrollment in this study. Informed consent will be obtained from patients acceptable to be included in the study. It will be noted if there is a history of gastrointestinal surgery and if the patient is nauseated before the contrast is administered.
Patients will be randomized to receive either a standardized dilution of Gastroview or Omnipaque orally. The two agents will be prepared to have nearly equivalent iodine concentration. No flavoring agent (ie Crystal Light) will be added. The plan is to mix the agents per manufacturer recommendation as follows:
Omnipaque 350 26cc in 974 cc of water (9.0g iodine) Gastroview 25cc in 1000cc of water (9.17g iodine)
The time the patients start and stop consuming the contrast as well as the volume taken and time from first drink to start of the scan will be recorded by a blinded investigator. Patients will be asked to drink 900cc. Technical staff will report any side effects or complications observed.
After completion of the CT scan, patients will fill in a survey rating the taste of the agent on a 5 point scale, and will be asked to report any side effects. Planned rating scale is as follows:
- 2=Dislike very much
1=Dislike moderately 0=Neither like nor dislike
- 1=Like moderately
- 2=Like very much
A taste test between the two agents will then be administered by a blinded investigator. Patients will be given 30 cc of each agent. The order in which the agents are administered will be randomized. Patients will be asked to rate preference, if any, for either agent on a 3 point scale. Potential bias related to which agent was administered for the CT will analyzed from the data.
Planned rating scale is as follows:
1- A is better 0 -no difference
- 1- B is better
Patients will be contacted by telephone the day after the CT to assess for any delayed side effects such as diarrhea, constipation, and abdominal cramping experienced in the 24 hours following.
Bowel opacification will be rated by 2 body imagers blinded to the agent the patient received. Degree of opacification of the stomach, duodenum, jejunum, and ileum will be rated on a 4 point scale. If contrast has reached the colon, ascending, transverse, descending and sigmoid will be similarly evaluated. Four point rating scale is as follows:
0= absent opacification
- minimal (<25% of analyzed segments opacified)
- good (>25 % and < 75% of analyzed segments opacified)
- excellent (> 75% of analyzed segments opacified)
Description of tests/procedures to be performed. Patients will undergo contrast enhanced abdominal pelvis CT as ordered by the referring clinician. Patients will be randomized to either dilute Omnipaque or dilute Gastroview for oral contrast. Both agents will be in a concentration of 9 mg of iodine/ml, and a volume of 900 cc.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00478556
|United States, Alabama|
|The Kirklin Clinic|
|Birmingham, Alabama, United States, 35249|
|Principal Investigator:||Michelle McNamara, MD||University of Alabama at Birmingham|